Literature DB >> 17351335

A dominant role for p53-dependent cellular senescence in radiosensitization of human prostate cancer cells.

Brian D Lehmann1, James A McCubrey, Holly S Jefferson, Matthew S Paine, William H Chappell, David M Terrian.   

Abstract

Because p53 inactivation may limit the effectiveness of radiation therapy for localized prostate cancer, it is important to understand how this gene regulates clonogenic survival after an exposure to ionizing radiation. Here, we show that premature cellular senescence is the principal mode of cell death accounting for the radiosensitivity of human prostate cancer cell lines retaining p53 function. Alternative stress response pathways controlled by this tumor suppressor, including cell cycle arrest, DNA damage repair, mitotic catastrophe and apoptosis, contributed significantly less to radiation-induced clonogenic death. Using a dominant negative C-terminal fragment of p53, we present the first evidence that a complete loss of endogenous p53 function is sufficient to limit the irradiation-induced senescence and clonogenic death of prostate cancer cells. Conversely, inheritance of wild-type p53 by prostate cancer cells lacking a functional allele of this gene (i.e., DU145) significantly increases clonogenic death through p53-dependent cellular senescence and apoptotic pathways. Our data provide evidence that mutations of even one p53 allele may be sufficient to alter their clonogenic fate. In addition, they support the idea that the p53 pathway can be used as a specific target for enhancing the radiosensitivity of prostate cancer cells. Activation of p53 by the drug nutlin-3 is shown to be an effective radiosensitizer of prostate cancer cells retaining functional alleles of p53 and this effect was entirely attributable to an increased induction of p53-dependent cellular senescence.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17351335     DOI: 10.4161/cc.6.5.3901

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  39 in total

Review 1.  Radiosensitization of prostate cancer by priming the wild-type p53-dependent cellular senescence pathway.

Authors:  Brian D Lehmann; James A McCubrey; David M Terrian
Journal:  Cancer Biol Ther       Date:  2007-08-05       Impact factor: 4.742

Review 2.  Twilight effects of low doses of ionizing radiation on cellular systems: a bird's eye view on current concepts and research.

Authors:  Ilaria Postiglione; Angela Chiaviello; Giuseppe Palumbo
Journal:  Med Oncol       Date:  2009-06-06       Impact factor: 3.064

Review 3.  Targeting the leukemic stem cell: the Holy Grail of leukemia therapy.

Authors:  N Misaghian; G Ligresti; L S Steelman; F E Bertrand; J Bäsecke; M Libra; F Nicoletti; F Stivala; M Milella; A Tafuri; M Cervello; A M Martelli; J A McCubrey
Journal:  Leukemia       Date:  2008-09-18       Impact factor: 11.528

4.  Distinct roles for p107 and p130 in Rb-independent cellular senescence.

Authors:  Brian D Lehmann; Adam M Brooks; Matthew S Paine; William H Chappell; James A McCubrey; David M Terrian
Journal:  Cell Cycle       Date:  2008-03-07       Impact factor: 4.534

5.  Alteration of Akt activity increases chemotherapeutic drug and hormonal resistance in breast cancer yet confers an achilles heel by sensitization to targeted therapy.

Authors:  James A McCubrey; Melissa L Sokolosky; Brian D Lehmann; Jackson R Taylor; Patrick M Navolanic; William H Chappell; Stephen L Abrams; Kristin M Stadelman; Ellis W T Wong; Negin Misaghian; Stefan Horn; Jörg Bäsecke; Massimo Libra; Franca Stivala; Giovanni Ligresti; Agostino Tafuri; Michele Milella; Marek Zarzycki; Andrzej Dzugaj; Francesca Chiarini; Camilla Evangelisti; Alberto M Martelli; David M Terrian; Richard A Franklin; Linda S Steelman
Journal:  Adv Enzyme Regul       Date:  2008-02-21

Review 6.  Targeting signal transduction pathways to eliminate chemotherapeutic drug resistance and cancer stem cells.

Authors:  James A McCubrey; Stephen L Abrams; Kristin Stadelman; William H Chappell; Michelle Lahair; Richard A Ferland; Linda S Steelman
Journal:  Adv Enzyme Regul       Date:  2009-11-04

7.  Interleukin-6 derived from cancer-associated fibroblasts attenuates the p53 response to doxorubicin in prostate cancer cells.

Authors:  Emarndeena H Cheteh; Victoria Sarne; Sophia Ceder; Julie Bianchi; Martin Augsten; Helene Rundqvist; Lars Egevad; Arne Östman; Klas G Wiman
Journal:  Cell Death Discov       Date:  2020-06-02

8.  Co-expression of CD147 and GLUT-1 indicates radiation resistance and poor prognosis in cervical squamous cell carcinoma.

Authors:  Xin-Qiong Huang; Xiang Chen; Xiao-Xue Xie; Qin Zhou; Kai Li; Shan Li; Liang-Fang Shen; Juan Su
Journal:  Int J Clin Exp Pathol       Date:  2014-03-15

9.  Senescence-associated exosome release from human prostate cancer cells.

Authors:  Brian D Lehmann; Matthew S Paine; Adam M Brooks; James A McCubrey; Randall H Renegar; Rong Wang; David M Terrian
Journal:  Cancer Res       Date:  2008-10-01       Impact factor: 12.701

Review 10.  Drugging the p53 pathway: understanding the route to clinical efficacy.

Authors:  Kian Hoe Khoo; Khoo Kian Hoe; Chandra S Verma; David P Lane
Journal:  Nat Rev Drug Discov       Date:  2014-03       Impact factor: 84.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.